Optimizing the use of thrombolytics in ST-segment elevation myocardial infarction

Area of Science:

• Cardiology
• Emergency Medicine
• Pharmacology

Background:

• Thrombolytic therapy is a vital treatment for ST-segment elevation myocardial infarction (STEMI), reducing mortality by up to 30% when administered promptly.
• Adjunctive treatments like aspirin, clopidogrel, and anti-thrombin agents enhance the effectiveness of thrombolytic therapy.
• Despite primary percutaneous coronary intervention (PCI) being the most effective reperfusion strategy, thrombolytic therapy remains a cornerstone due to limited PCI availability in many hospitals.

Purpose of the Study:

• To review the current role and advancements in thrombolytic therapy for STEMI.
• To highlight the importance of timely reperfusion and explore strategies for earlier treatment.
• To discuss the limitations of current thrombolytic approaches and the need for improved predictive markers.

Main Methods:

• Review of clinical trials and evidence regarding thrombolytic therapy for STEMI.
• Analysis of outcomes associated with different treatment strategies, including adjunctive medications and reperfusion methods.
• Examination of ongoing research into pre-hospital administration and optimized timing of interventions.

Main Results:

• Thrombolytic therapy can achieve initial infarct-related artery patency rates approaching 85%.
• Early administration of thrombolysis yields the greatest mortality benefit.
• Facilitated PCI (thrombolysis followed by immediate PCI) has not demonstrated added benefit.

Conclusions:

• Thrombolytic therapy remains a critical treatment for STEMI, especially in settings without immediate PCI capabilities.
• Further research is needed to identify non-invasive markers predicting thrombolytic failure or re-occlusion.
• Optimizing the timing of reperfusion, including pre-hospital interventions, is a key focus for improving STEMI patient outcomes.